Compare · GKOS vs MDLN
GKOS vs MDLN
Side-by-side comparison of Glaukos Corporation (GKOS) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GKOS and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $52.27B, about 5.7x GKOS ($9.21B).
- GKOS has been more active in the news (16 items in the past 4 weeks vs 4 for MDLN).
- Both have 25 recent analyst ratings on file.
- Company
- Glaukos Corporation
- Medline Inc.
- Price
- $156.81+0.90%
- $39.80-3.23%
- Market cap
- $9.21B
- $52.27B
- 1M return
- -
- +7.36%
- 1Y return
- -
- -2.33%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- 2025
- News (4w)
- 16
- 4
- Recent ratings
- 25
- 25
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Latest GKOS
- SVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,550,000 worth of shares (10,000 units at $155.00) as part of a pre-agreed trading plan (SEC Form 4)
- SVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,500,000 worth of shares (10,000 units at $150.00) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $99,567 worth of shares (716 units at $139.06) as part of a pre-agreed trading plan, decreasing direct ownership by 0.81% to 87,634 units (SEC Form 4)
- Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
- H.C. Wainwright initiated coverage on Glaukos with a new price target
- CHAIRMAN & CEO Burns Thomas William covered exercise/tax liability with 4,059 shares, decreasing direct ownership by 6% to 68,967 units (SEC Form 4) to satisfy withholding obligation
- PRESIDENT & COO Gilliam Joseph E covered exercise/tax liability with 1,056 shares, decreasing direct ownership by 1% to 72,363 units (SEC Form 4) to satisfy withholding tax
- CHIEF DEVELOPMENT OFFICER Navratil Tomas covered exercise/tax liability with 483 shares, decreasing direct ownership by 0.54% to 88,350 units (SEC Form 4) to satisfy withholding tax
- Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
- Amendment: SEC Form 4 filed by Director Foley Mark J
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)